HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis.

Abstract
Hyperforin is a plant derived antibiotic from St. John's wort. Here we describe a novel activity of hyperforin, namely its ability to inhibit the growth of tumour cells by induction of apoptosis. Hyperforin inhibited the growth of various human and rat tumour cell lines in vivo, with IC(50) values between 3-15 microM. Treatment of tumour cells with hyperforin resulted in a dose-dependent generation of apoptotic oligonucleosomes, typical DNA-laddering and apoptosis-specific morphological changes. In MT-450 mammary carcinoma cells hyperforin increased the activity of caspase-9 and caspase-3, and hyperforin-mediated apoptosis was blocked by the broad-range caspase inhibitor zVAD.fmk. When added to MT-450 cells, hyperforin, but not paclitaxel, induced a rapid loss of the mitochondrial transmembrane potential Deltapsi(m), and subsequent morphological changes such as homogenization and vacuolization of mitochondria. Monitoring of Deltapsi(m) revealed that the hyperforin-mediated mitochondrial permeability transition can not be prevented by zVAD.fmk. This indicates that mitochondrial permeabilization is a cause rather than a consequence of caspase activation. Moreover, hyperforin was capable of releasing cytochrome c from isolated mitochondria. These findings suggest that hyperforin activates a mitochondria-mediated apoptosis pathway. In vivo, hyperforin inhibited the growth of autologous MT-450 breast carcinoma in immunocompetent Wistar rats to a similar extent as the cytotoxic drug paclitaxel, without any signs of acute toxicity. Owing to the combination of significant antitumour activity, low toxicity in vivo and natural abundance of the compound, hyperforin holds the promise of being an interesting novel antineoplastic agent that deserves further laboratory and in vivo exploration.
AuthorsChristoph M Schempp, Vladimir Kirkin, Birgit Simon-Haarhaus, Astrid Kersten, Judit Kiss, Christian C Termeer, Bernhard Gilb, Thomas Kaufmann, Christoph Borner, Jonathan P Sleeman, Jan C Simon
JournalOncogene (Oncogene) Vol. 21 Issue 8 Pg. 1242-50 (Feb 14 2002) ISSN: 0950-9232 [Print] England
PMID11850844 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Bridged Bicyclo Compounds
  • Cytochrome c Group
  • Terpenes
  • Phloroglucinol
  • Caspases
  • Staurosporine
  • hyperforin
Topics
  • Animals
  • Antineoplastic Agents (chemistry, pharmacology)
  • Apoptosis (drug effects)
  • Bridged Bicyclo Compounds
  • Caspases (metabolism)
  • Cell Division (drug effects)
  • Cytochrome c Group (metabolism)
  • Dose-Response Relationship, Drug
  • Enzyme Activation (drug effects)
  • Female
  • Humans
  • Hypericum (chemistry)
  • Intracellular Membranes (drug effects, metabolism)
  • Microscopy, Electron
  • Mitochondria (drug effects, metabolism, ultrastructure)
  • Neoplasms (enzymology, pathology, ultrastructure)
  • Phloroglucinol (analogs & derivatives)
  • Rats
  • Staurosporine (pharmacology)
  • Terpenes (chemistry, pharmacology)
  • Time Factors
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: